EMD Serono forms partnership to discover MS treatments

03/19/2009 | Mass High Tech (Boston)

EMD Serono, a biopharmaceutical unit of Merck KGaA, signed a two-year agreement with the National Multiple Sclerosis Society to speed up research and development of treatments for multiple sclerosis. Under the deal, Merck will invest as much as $19 million in the joint venture and EMD will work with Fast Forward, the society's nonprofit subsidiary.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL